STOCK TITAN

[144] Sionna Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Sionna Therapeutics (SION) submitted a Form 144 notice indicating a proposed sale of 11,468 common shares through Merrill Lynch in San Francisco. The filing lists an aggregate market value of $331,883.92 and shows 44,139,823 shares outstanding for the issuer. The shares were originally acquired by private placement from the issuer on 03/04/2024 and were paid in cash on that date. The filing states the approximate sale date as 09/29/2025 and names NASDAQ as the exchange. No securities were reported sold in the past three months.

Sionna Therapeutics (SION) ha presentato un avviso Form 144 che indica una vendita proposta di 11.468 azioni ordinarie tramite Merrill Lynch a San Francisco. Il deposito riporta un valore di mercato aggregato di 331.883,92 dollari e mostra 44.139.823 azioni in circolazione dell emittente. Le azioni sono state originariamente acquisite tramite collocamento privato dall emittente il 03/04/2024 e sono state pagate in contanti in quella data. Il deposito indica come data di vendita approssimativa il 29/09/2025 e nomina NASDAQ come scambio. Nessun titolo è stato riferito venduto negli ultimi tre mesi.

Sección Sionna Therapeutics (SION) presentó un aviso Form 144 que indica una venta propuesta de 11.468 acciones comunes a través de Merrill Lynch en San Francisco. El archivo registra un valor de mercado agregado de 331.883,92 dólares y muestra 44.139.823 acciones en circulación de la emsitente. Las acciones fueron adquiridas originalmente mediante colocación privada de la emsitera el 03/04/2024 y se pagaron en efectivo en esa fecha. El archivo indica la fecha aproximada de venta como el 29/09/2025 y nombra a NASDAQ como la bolsa. No se reportaron ventas de valores en los últimos tres meses.

Sionna Therapeutics (SION)은 샌프란시스코에서 Merrill Lynch를 통해 11,468 주의 일반 주식 매각 제안을 나타내는 Form 144 공시를 제출했습니다. 제출 문서는 총 시장가치 331,883.92 달러를 기재하고 발행사의 44,139,823 주의 발행 주식을 보여줍니다. 이 주식은 발행사로부터 비공개 배정으로 원래 취득되었으며, 해당 날짜에 현금으로 지급되었습니다. 공시는 매각 예정일을 2025년 9월 29일로 대략 제시하고 거래소로 NASDAQ을 명시합니다. 지난 3개월 동안 매각된 증권은 보고되지 않았습니다.

Sionna Therapeutics (SION) a soumis un avis Form 144 indiquant une vente proposée de 11 468 actions ordinaires via Merrill Lynch à San Francisco. Le dépôt indique une valeur marchande brute de 331 883,92 dollars et montre 44 139 823 actions en circulation de l émetteur. Les actions ont été initialement acquises par placement privé auprès de l émetteur le 04/03/2024 et ont été payées en espèces à cette date. Le dépôt indique la date de vente approximative au 29/09/2025 et nomme NASDAQ comme bourse. Aucun titre n a été vendu au cours des trois derniers mois.

Sionna Therapeutics (SION) hat eine Form 144-Mitteilung eingereicht, die einen vorgeschlagenen Verkauf von 11.468 Stammaktien über Merrill Lynch in San Francisco anzeigt. Die Einreichung listet einen aggregierten Marktwert von 331.883,92 USD und zeigt 44.139.823 ausstehende Aktien des Emittenten. Die Aktien wurden ursprünglich durch Private Placement vom Emittenten am 04.03.2024 erworben und an diesem Datum bar bezahlt. Die Einreichung nennt als ungefähres Verkaufsdatum den 29.09.2025 und benennt NASDAQ als Börse. In den letzten drei Monaten wurden keine Wertpapiere verkauft gemeldet.

قدمت Sionna Therapeutics (SION) إشعار Form 144 يشير إلى بيع مقترح لـ 11,468 من الأسهم العادية من خلال Merrill Lynch في سان فرانسيسكو. يبيّن الملف قيمة سوقية إجمالية قدرها 331,883.92 دولار ويظهر عدد 44,139,823 سهمًا قائمًا للمصدر. تم الحصول على الأسهم في الأصل من خلال طرح خاص من المصدر في تاريخ 03/04/2024 وتم دفع ثمنها نقدًا في ذلك التاريخ. يذكر الملف تاريخ بيع تقريبي في 29/09/2025 ويذكر NASDAQ كالبورصة. لم يتم الإبلاغ عن أي أوراق مالية مُباعة في الأشهر الثلاثة الماضية.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Form 144 notifies a planned sale of 11,468 common shares valued at $331,883.92, acquired via private placement on 03/04/2024.

The filing documents a proposed sale through Merrill Lynch on NASDAQ with an approximate sale date of 09/29/2025. It discloses acquisition details showing the shares came from a private placement and were paid for in cash on 03/04/2024. The filer reports no sales in the prior three months. From a disclosure standpoint, the notice meets Rule 144 presentation requirements by naming broker, share count, market value, acquisition date and payment method.

TL;DR: The Form 144 provides required seller and transaction details but contains no additional context on insider status or trading plan.

The form affirms the seller represents no undisclosed material adverse information and includes standard cautions about misstatements. It notes the securities were acquired in a private placement and will be sold via Merrill Lynch on NASDAQ. The filing does not include any plan adoption date or 10b5-1 plan specifics, and it reports no securities sold in the past three months.

Sionna Therapeutics (SION) ha presentato un avviso Form 144 che indica una vendita proposta di 11.468 azioni ordinarie tramite Merrill Lynch a San Francisco. Il deposito riporta un valore di mercato aggregato di 331.883,92 dollari e mostra 44.139.823 azioni in circolazione dell emittente. Le azioni sono state originariamente acquisite tramite collocamento privato dall emittente il 03/04/2024 e sono state pagate in contanti in quella data. Il deposito indica come data di vendita approssimativa il 29/09/2025 e nomina NASDAQ come scambio. Nessun titolo è stato riferito venduto negli ultimi tre mesi.

Sección Sionna Therapeutics (SION) presentó un aviso Form 144 que indica una venta propuesta de 11.468 acciones comunes a través de Merrill Lynch en San Francisco. El archivo registra un valor de mercado agregado de 331.883,92 dólares y muestra 44.139.823 acciones en circulación de la emsitente. Las acciones fueron adquiridas originalmente mediante colocación privada de la emsitera el 03/04/2024 y se pagaron en efectivo en esa fecha. El archivo indica la fecha aproximada de venta como el 29/09/2025 y nombra a NASDAQ como la bolsa. No se reportaron ventas de valores en los últimos tres meses.

Sionna Therapeutics (SION)은 샌프란시스코에서 Merrill Lynch를 통해 11,468 주의 일반 주식 매각 제안을 나타내는 Form 144 공시를 제출했습니다. 제출 문서는 총 시장가치 331,883.92 달러를 기재하고 발행사의 44,139,823 주의 발행 주식을 보여줍니다. 이 주식은 발행사로부터 비공개 배정으로 원래 취득되었으며, 해당 날짜에 현금으로 지급되었습니다. 공시는 매각 예정일을 2025년 9월 29일로 대략 제시하고 거래소로 NASDAQ을 명시합니다. 지난 3개월 동안 매각된 증권은 보고되지 않았습니다.

Sionna Therapeutics (SION) a soumis un avis Form 144 indiquant une vente proposée de 11 468 actions ordinaires via Merrill Lynch à San Francisco. Le dépôt indique une valeur marchande brute de 331 883,92 dollars et montre 44 139 823 actions en circulation de l émetteur. Les actions ont été initialement acquises par placement privé auprès de l émetteur le 04/03/2024 et ont été payées en espèces à cette date. Le dépôt indique la date de vente approximative au 29/09/2025 et nomme NASDAQ comme bourse. Aucun titre n a été vendu au cours des trois derniers mois.

Sionna Therapeutics (SION) hat eine Form 144-Mitteilung eingereicht, die einen vorgeschlagenen Verkauf von 11.468 Stammaktien über Merrill Lynch in San Francisco anzeigt. Die Einreichung listet einen aggregierten Marktwert von 331.883,92 USD und zeigt 44.139.823 ausstehende Aktien des Emittenten. Die Aktien wurden ursprünglich durch Private Placement vom Emittenten am 04.03.2024 erworben und an diesem Datum bar bezahlt. Die Einreichung nennt als ungefähres Verkaufsdatum den 29.09.2025 und benennt NASDAQ als Börse. In den letzten drei Monaten wurden keine Wertpapiere verkauft gemeldet.

قدمت Sionna Therapeutics (SION) إشعار Form 144 يشير إلى بيع مقترح لـ 11,468 من الأسهم العادية من خلال Merrill Lynch في سان فرانسيسكو. يبيّن الملف قيمة سوقية إجمالية قدرها 331,883.92 دولار ويظهر عدد 44,139,823 سهمًا قائمًا للمصدر. تم الحصول على الأسهم في الأصل من خلال طرح خاص من المصدر في تاريخ 03/04/2024 وتم دفع ثمنها نقدًا في ذلك التاريخ. يذكر الملف تاريخ بيع تقريبي في 29/09/2025 ويذكر NASDAQ كالبورصة. لم يتم الإبلاغ عن أي أوراق مالية مُباعة في الأشهر الثلاثة الماضية.

Sionna Therapeutics(SION)提交了一份 Form 144 通知,宣布拟通过 Merrill Lynch 在旧金山出售 11,468 股普通股。该备案列出 总市值 331,883.92 美元,并显示发行人流通股数为 44,139,823 股。这些股票最初于 2024-03-04 通过向发行人进行私募取得,且在当天以现金支付。备案将拟议销售日期大致定为 2025-09-29,并将 NASDAQ 列为交易所。过去三个月内未有证券被报告出售。

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for SION report?

The Form 144 reports a proposed sale of 11,468 common shares with an aggregate market value of $331,883.92 via Merrill Lynch, with an approximate sale date of 09/29/2025.

When and how were the shares being sold on the Form 144 acquired?

The shares were acquired in a private placement from the issuer on 03/04/2024 and paid for in cash on that date.

Which broker and exchange are listed on the SION Form 144?

The broker is listed as Merrill Lynch, 555 California Street, 18th Floor, San Francisco, CA 94104 and the exchange is NASDAQ.

Does the Form 144 show recent sales by the same person?

No. The filing indicates Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

What representation does the filer make about material information?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Sionna Therapeutics

NASDAQ:SION

SION Rankings

SION Latest News

SION Latest SEC Filings

SION Stock Data

1.75B
29.38M
7.01%
97.98%
7.87%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM